Jean-Richard Eveillard

Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Relapsed/Refractory Multiple Myeloma Refractory to an IMiD or Proteasome Inhibitor: Updated Analysis of the Phase 1 ANCHOR Study (OP-104)

Purpose of the Study: Despite recent therapeutic advances, multiple myeloma (MM) remains incurable. Melflufen is a lipophilic peptide-conjugated alkylator that rapidly delivers a highly c...

Yvonne A. Efebera ;

Miquel Granell ;

Paul G. Richardson ;

Roman Hajek ;

Maria-Victoria Mateos ;

Albert Oriol ;

Jacques Delaunay ;

Katell Le Du ;

Jean-Richard Eveillard ;

Lionel Karlin ;

Vladimir Maisnar ;

Joaquin Martinez-Lopez ;

Maxim Norkin ;

Jan Staub ;

Catriona Byrne ;

Malin Sydvander ;

Enrique M. Ocio ;

Vincent Ribrag , MD;

Ludk Pour ;

10/22/2019

Featured CME

The Medication Access and Training Expansion (MATE) Act requires prescribers renewing their DEA registration to have completed at least 8 hours of training on opioid or other substance use disorders.

Upcoming Events

April 5 ⁠–⁠ April 6

April 21 ⁠–⁠ April 24

April 29 ⁠–⁠ April 30

April 30 ⁠–⁠ May 4

May 1 ⁠–⁠ May 2

May 7 ⁠–⁠ May 9

May 8 ⁠–⁠ May 10

May 14 ⁠–⁠ May 16

May 19 ⁠–⁠ May 21

May 28 ⁠–⁠ May 31

See Full Calendar

Jean-Richard Eveillard

Featured CME

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products